The bivalent COVID-19 vaccine developed by GSK and Sanofi shows promising results with a 64.7% overall effectiveness against symptomatic COVID-19, according to a phase 3 trial. The vaccine performs especially well as a booster, achieving 75.9% efficacy in non-naïve subjects.
COVID Summer Wave? American Nurse Kidnapped; Fatal Brain-Eating Amoeba Case
Note that some links may require registration or subscription. Though case counts on the whole remain low, the CDC is reporting an uptick in COVID